Biocryst Pharmaceuticals Inc (BCRX)

5.15
0.09 1.72
NASDAQ : Health Care
Prev Close 5.24
Open 5.29
Day Low/High 5.11 / 5.34
52 Wk Low/High 1.63 / 15.96
Volume 1.02M
Avg Volume 1.82M
Exchange NASDAQ
Shares Outstanding 80.42M
Market Cap 440.70M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)

BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of BCRX December 15th Options Trading

First Week of BCRX December 15th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the December 15th expiration.

BioCryst Announces Mundipharma Receives Approval For Mundesine® In Japan

BioCryst Announces Mundipharma Receives Approval For Mundesine® In Japan

A Treatment for Relapsed/Refractory Peripheral T-Cell Lymphoma

Biotech Premarket Movers: Esperion, Minerva and BioCryst

Biotech Premarket Movers: Esperion, Minerva and BioCryst

Esperion Therapeutics, Minerva Neurosciences and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Wait for the Pullback on BioCryst Pharmaceuticals

Prices are extended so don't go long just yet.

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharmaceuticals, BioCryst Pharmaceuticals and Curis were among the biotech stock movers in premarket trading on Thursday.

BioCryst Pharmaceuticals Reaches Analyst Target Price

BioCryst Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of BioCryst Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $7.78, changing hands for $7.80/share.

Everything We Know About BioCryst's New HAE Drug

Everything We Know About BioCryst's New HAE Drug

BioCryst's Hereditary angioedema drug-trial results not compelling.

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

BioCryst Pharmaceuticals, Sangamo Therapeutics and Cempra were among the biotech stock movers in premarket trading on Monday.

BioCryst Pharmaceuticals Stock Drops After Reporting 4Q Loss

BioCryst Pharmaceuticals Stock Drops After Reporting 4Q Loss

Shares of BioCryst (BCRX) fell double digits despite topping analysts' 4Q expectations.

Notable Thursday Option Activity: BCRX, AXDX, HUM

Notable Thursday Option Activity: BCRX, AXDX, HUM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioCryst Pharmaceuticals, Inc. , where a total of 16,282 contracts have traded so far, representing approximately 1.6 million underlying shares.

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Synergy Pharmaceuticals, Arrowhead Pharmaceuticals and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.

Commit To Buy BioCryst Pharmaceuticals At $3, Earn 52.5% Annualized Using Options

Commit To Buy BioCryst Pharmaceuticals At $3, Earn 52.5% Annualized Using Options

Investors considering a purchase of BioCryst Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.90/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Big-Cap Tech Names, Biotechs, Oils Lifting Market

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The number of new 12-month highs has climbed to 240.

Finally Getting Back to a Stock Picker's Market

Finally Getting Back to a Stock Picker's Market

The euphoria has calmed down, and if stocks can consolidate, we will have some better entry points.

Shark Bites: What, Market Worry?

Shark Bites: What, Market Worry?

Talk about Dow 20,000 is probably feeding off itself.